Ibrutinib- and bortezomib-extended R-CHOP induction in elderly higher-risk patients newly diagnosed with diffuse large B-cell lymphoma - first analysis of toxicity and efficacy signals

被引：3

作者：

Denker, Sophy ^{[1
,2
,3
,4
]}

Bittner, Aitomi ^{[1
,2
,3
,4
]}

Frick, Mareike ^{[1
,2
,3
]}

Kase, Julia ^{[1
,2
,3
]}

Hoffmann, Joerg ^{[5
]}

Trenker, Corinna ^{[5
]}

Keller, Ulrich ^{[1
,2
,3
,6
,7
,8
]}

Bogner, Christian ^{[9
]}

Huettmann, Andreas ^{[10
]}

Duerig, Jan ^{[10
]}

Janz, Martin ^{[1
,2
,3
,8
]}

Mathas, Stephan ^{[1
,2
,3
,8
]}

Marks, Reinhard ^{[11
,12
]}

Krohn, Ulrike ^{[11
,12
]}

Na, Il-Kang ^{[1
,2
,3
,4
,6
,7
,13
]}

Bullinger, Lars ^{[1
,2
,3
]}

Schmitt, Clemens A. ^{[1
,2
,3
,14
]}

机构：

[1] Charite Univ Med Berlin, Berlin, Germany

[2] Free Univ Berlin, Med Dept, Div Hematol Oncol & Tumor Immunol, Charitepl 1, D-10117 Berlin, Germany

[3] Humboldt Univ, Charitepl 1, D-10117 Berlin, Germany

[4] Charite Univ Med Berlin, Berlin Inst Hlth, Berlin, Germany

[5] Philipps Univ Marburg, Univ Hosp Giessen & Marburg, Dept Hematol Oncol Immunol, Marburg, Germany

[6] German Canc Res Ctr, Heidelberg, Germany

[7] German Canc Consortium DKTK, Heidelberg, Germany

[8] Helmholtz Assoc, Max Delbruck Ctr Mol Med, Berlin, Germany

[9] Tech Univ Munich, Med Clin & Policlin 2, Klinikum Rechts Isar, Munich, Germany

[10] Univ Duisburg Essen, Klin Hamatol, Univ Klinikum Essen, Essen, Germany

[11] Univ Freiburg, Fac Med, Dept Hematol Oncol Stem Cell Transplantat, Freiburg, Germany

[12] Univ Freiburg, Med Ctr, Dept Hematol Oncol Stem Cell Transplantat, Freiburg, Germany

[13] Max Delbruck Ctr Mol Med, Expt & Clin Res Ctr ECRC, Berlin, Germany

[14] Johannes Kepler Univ Linz, Kepler Univ Hosp, Dept Hematol & Oncol, Linz, Austria

来源：

LEUKEMIA & LYMPHOMA | 2022年 / 63卷 / 01期

关键词：

Lymphoma and Hodgkin disease; biomarker; novel study design; targeted therapy; prediction; diffuse large B-cell lymphoma; RITUXIMAB PLUS CYCLOPHOSPHAMIDE; RANDOMIZED CONTROLLED-TRIAL; MOLECULAR CHARACTERISTICS; CHEMOTHERAPY; MULTICENTER; VINCRISTINE; DOXORUBICIN; THERAPY; AGE;

D O I：

10.1080/10428194.2021.1964024

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Diffuse large-cell B-cell lymphoma (DLBCL) is the most common lymphoid malignancy. About 30-40% of the patients will not be cured by standard Rituximab (R)-CHOP-like immune-chemotherapy, and many of them experience relapse and eventually succumb to their disease. Enhancing first-line efficacy in patients at higher risk, among them many elderly, is key to improve long-term outcomes. Numerous attempts to combine R-CHOP with targeted agents failed in large randomized phase III trials. The addition of Ibrutinib enhanced survival in younger patients, but increased toxicity across all age groups, especially in the elderly. Older DLBCL patients impose particular challenges, since they often present with more advanced disease, and exhibit treatment-relevant comorbidities. ImbruVeRCHOP trial aims at identifying patients who need that benefit from rationally augmented first-line regimens without experiencing overt toxicity and detecting their molecular signatures of response. This first analysis presents encouraging feasibility, safety, and preliminary response data in elderly high-risk DLBCL patients.

引用

页码：84 / 92

页数：9

共 32 条

[1] Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303 [J].

Bartlett, Nancy L. ;

Wilson, Wyndham H. ;

Jung, Sin-Ho ;

Hsi, Eric D. ;

Maurer, Matthew J. ;

Pederson, Levi D. ;

Polley, Mei-Yin C. ;

Pitcher, Brandelyn N. ;

Cheson, Bruce D. ;

Kahl, Brad S. ;

Friedberg, Jonathan W. ;

Staudt, Louis M. ;

Wagner-Johnston, Nina D. ;

Blum, Kristie A. ;

Abramson, Jeremy S. ;

Reddy, Nishitha M. ;

Winter, Jane N. ;

Chang, Julie E. ;

Gopal, Ajay K. ;

Chadburn, Amy ;

Mathew, Susan ;

Fisher, Richard I. ;

Richards, Kristy L. ;

Schoder, Heiko ;

Zelenetz, Andrew D. ;

Leonard, John P. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (21) :1790-+

[2] A longitudinal study of non-medical determinants of adherence to R-CHOP therapy for diffuse large B-cell lymphoma: implication for survival [J].

Borel, Cecile ;

Lamy, Sebastien ;

Compaci, Gisele ;

Recher, Christian ;

Jeanneau, Pauline ;

Nogaro, Jean Claude ;

Bauvin, Eric ;

Despas, Fabien ;

Delpierre, Cyrille ;

Laurent, Guy .

BMC CANCER, 2015, 15

[3] Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes [J].

Chapuy, Bjoern ;

Stewart, Chip ;

Dunford, Andrew J. ;

Kim, Jaegil ;

Kamburov, Atanas ;

Redd, Robert A. ;

Lawrence, Mike S. ;

Roemer, Margaretha G. M. ;

Li, Amy J. ;

Ziepert, Marita ;

Staiger, Annette M. ;

Wala, Jeremiah A. ;

Ducar, Matthew D. ;

Leshchiner, Ignaty ;

Rheinbay, Ester ;

Taylor-Weiner, Amaro ;

Coughlin, Caroline A. ;

Hess, Julian M. ;

Pedamallu, Chandra S. ;

Livitz, Dimitri ;

Rosebrock, Daniel ;

Rosenberg, Mara ;

Tracy, Adam A. ;

Horn, Heike ;

van Hummelen, Paul ;

Feldman, Andrew L. ;

Link, Brian K. ;

Novak, Anne J. ;

Cerhan, James R. ;

Habermann, Thomas M. ;

Siebert, Reiner ;

Rosenwald, Andreas ;

Thorner, Aaron R. ;

Meyerson, Matthew L. ;

Golub, Todd R. ;

Beroukhim, Rameen ;

Wulf, Gerald G. ;

Ott, German ;

Rodig, Scott J. ;

Monti, Stefano ;

Neuberg, Donna S. ;

Loeffler, Markus ;

Pfreundschuh, Michael ;

Truemper, Lorenz ;

Getz, Gad ;

Shipp, Margaret A. .

NATURE MEDICINE, 2018, 24 (05) :679-+

[4] Revised response criteria for malignant lymphoma [J].

Cheson, Bruce D. ;

Pfistner, Beate ;

Juweid, Malik E. ;

Gascoyne, Randy D. ;

Specht, Lena ;

Horning, Sandra J. ;

Coiffier, Bertrand ;

Fisher, Richard I. ;

Hagenbeek, Anton ;

Zucca, Emanuele ;

Rosen, Steven T. ;

Stroobants, Sigrid ;

Lister, T. Andrew ;

Hoppe, Richard T. ;

Dreyling, Martin ;

Tobinai, Kensei ;

Vose, Julie M. ;

Connors, Joseph M. ;

Federico, Massimo ;

Diehl, Volker .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :579-586

[5] CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].

Coiffier, B ;

Lepage, E ;

Brière, J ;

Herbrecht, R ;

Tilly, H ;

Bouabdallah, R ;

Morel, P ;

Van den Neste, E ;

Salles, G ;

Gaulard, P ;

Reyes, F ;

Gisselbrecht, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242

[6] Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles [J].

Cunningham, David ;

Hawkes, Eliza A. ;

Jack, Andrew ;

Qian, Wendi ;

Smith, Paul ;

Mouncey, Paul ;

Pocock, Christopher ;

Ardeshna, Kirit M. ;

Radford, John A. ;

McMillan, Andrew ;

Davies, John ;

Turner, Deborah ;

Kruger, Anton ;

Johnson, Peter ;

Gambell, Joanna ;

Linch, David .

LANCET, 2013, 381 (9880) :1817-1826

[7] Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial [J].

Davies, Andrew ;

Cummin, Thomas E. ;

Barrans, Sharon ;

Maishman, Tom ;

Mamot, Christoph ;

Novak, Urban ;

Caddy, Josh ;

Stanton, Louise ;

Kazmi-Stokes, Shamim ;

McMillan, Andrew ;

Fields, Paul ;

Pocock, Christopher ;

Collins, Graham P. ;

Stephens, Richard ;

Cucco, Francesco ;

Clipson, Alexandra ;

Sha, Chulin ;

Tooze, Reuben ;

Care, Matthew A. ;

Griffiths, Gareth ;

Du, Ming-Qing ;

Westhead, David R. ;

Burton, Catherine ;

Johnson, Peter W. M. .

LANCET ONCOLOGY, 2019, 20 (05) :649-662

[8]

Denker Sophy, 2019, Int J Hematol Oncol, V8, pIJH20, DOI 10.2217/ijh-2019-0010

[9] Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial [J].

Duehrsen, Ulrich ;

Mueller, Stefan ;

Hertenstein, Bernd ;

Thomssen, Henrike ;

Kotzerke, Joerg ;

Mesters, Rolf ;

Berdel, Wolfgang E. ;

Franzius, Christiane ;

Kroschinsky, Frank ;

Weckesser, Matthias ;

Kofahl-Krause, Dorothea ;

Bengel, Frank M. ;

Duerig, Jan ;

Matschke, Johannes ;

Schmitz, Christine ;

Poeppel, Thorsten ;

Ose, Claudia ;

Brinkmann, Marcus ;

La Rosee, Paul ;

Freesmeyer, Martin ;

Hertel, Andreas ;

Hoeffkes, Heinz-Gert ;

Behringer, Dirk ;

Prange-Krex, Gabriele ;

Wilop, Stefan ;

Krohn, Thomas ;

Holzinger, Jens ;

Griesshammer, Martin ;

Giagounidis, Aristoteles ;

Raghavachar, Aruna ;

Maschmeyer, Georg ;

Brink, Ingo ;

Bernhard, Helga ;

Haberkorn, Uwe ;

Gaska, Tobias ;

Kurch, Lars ;

van Assema, Danielle M. E. ;

Klapper, Wolfram ;

Hoelzer, Dieter ;

Geworski, Lilli ;

Joeckel, Karl-Heinz ;

Scherag, Andre ;

Bockisch, Andreas ;

Rekowski, Jan ;

Huettmann, Andreas .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (20) :2024-+

[10] Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma [J].

Facon, Thierry ;

Lee, Jae Hoon ;

Moreau, Philippe ;

Niesvizky, Ruben ;

Dimopoulos, Meletios ;

Hajek, Roman ;

Pour, Ludek ;

Jurczyszyn, Artur ;

Qiu, Lugui ;

Klippel, Zandra ;

Zahlten-Kumeli, Anita ;

Osman, Muhtarjan ;

Paiva, Bruno ;

San-Miguel, Jesus .

BLOOD, 2019, 133 (18) :1953-1963

← 1 2 3 4 →